成都欧林生物科技股份有限公司关于自愿披露四价流感病毒裂解疫苗(MDCK细胞)启动Ⅲ期临床试验并完成首例受试者入组的公告

Core Viewpoint - Chengdu Olin Biological Technology Co., Ltd. has officially launched the Phase III clinical trial of its quadrivalent influenza virus split vaccine (MDCK cells) and completed the enrollment of the first subject, marking a significant milestone in the vaccine's development [1][4]. Group 1: Vaccine Overview - The quadrivalent influenza virus split vaccine (MDCK cells) is designed for individuals aged 6 months and older, aiming to stimulate the immune system to produce antibodies against influenza viruses, thereby preventing influenza outbreaks [1]. - The vaccine is a cell-based influenza vaccine, which allows for higher production yields, more stable product quality, and lower production costs compared to traditional methods [2]. Group 2: Clinical Trial Details - The Phase III clinical trial employs a randomized, blinded, positive-controlled design to further evaluate the efficacy and safety of the quadrivalent influenza virus split vaccine (MDCK cells), providing scientific evidence for regulatory approval [3]. Group 3: Impact on the Company - The quadrivalent influenza virus split vaccine represents a key focus in the company's viral vaccine portfolio, indicating significant progress in vaccine research and development, which will enhance the company's product pipeline and support sustainable growth [4].